Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Dow
McKinsey
Johnson and Johnson
Express Scripts

Last Updated: August 10, 2022

Investigational Drug Information for Chiauranib


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Chiauranib?

Chiauranib is an investigational drug.

There have been 13 clinical trials for Chiauranib. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2021.

The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd., Medelis Inc., and H & J CRO International, Inc.

There is one US patent protecting this investigational drug.

Recent Clinical Trials for Chiauranib
TitleSponsorPhase
Mass Balance Study of [14C]ChiauranibChipscreen Biosciences, Ltd.N/A
Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy VolunteersH & J CRO International, Inc.Phase 1
Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy VolunteersChipscreen Biosciences, Ltd.Phase 1

See all Chiauranib clinical trials

Clinical Trial Summary for Chiauranib

Top disease conditions for Chiauranib
Top clinical trial sponsors for Chiauranib

See all Chiauranib clinical trials

US Patents for Chiauranib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Chiauranib See Plans and Pricing Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Dow
McKinsey
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.